CMBA
STLN

C.M. Bidwell & Associates’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

C.M. Bidwell & Associates’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-265
Closed -$925 – 533
2025
Q3 		$925 Buy
+265
New +$908 ﹤0.01% 434

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C.M. Bidwell & Associates's STLN Position: Q4 2025 in Review

C.M. Bidwell & Associates sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2025, closing a stake of 265 shares — an estimated $925 sold.

C.M. Bidwell & Associates first reported a position in STLN in Q3 2025 and held it in 1 quarter. The position peaked at $925 in Q3 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • C.M. Bidwell & Associates reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 265 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $925.
  • C.M. Bidwell & Associates first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Starling Oncology Institute, Inc. Common Stock position peaked at $925 in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2025, filed 13 Feb 2026.